Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Mitoimmune Therapeutics Inc. manages a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This specific action is located in 1 distinct art unit. A practitioner managing this portfolio interacts with 1 distinct examiner to address the outstanding issues.
The busiest examiner for this entity is REDWOOD, CHRISTOPHER EVAN, who is currently responsible for 1 busiest examiner pending office action. This figure matches the total number of 1 pending office action for the entire portfolio. This means the prosecution workload is entirely handled by this examiner. Such a structure allows for a direct and consistent dialogue between the applicant and the USPTO.
Because the work is limited to 1 distinct art unit, the technical arguments required for these filings are specific to that unit's standards. The presence of 1 distinct examiner means that the legal strategy does not need to account for different examiner behaviors across the applications. The data shows a prosecution environment where all active matters are funneled through REDWOOD, CHRISTOPHER EVAN, which simplifies the administrative oversight of the Mitoimmune Therapeutics Inc. company patent portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDWOOD, CHRISTOPHER EVAN | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554679 | SULFATE OF 5-[(1,1-DIOXIDO-4-THIOMORPHOLINYL)METHYL]-2-PHENYL-N-(TETRAHYDRO-2H-PYRAN-4-YL)-1H-INDOLE-7-AMINE, AND NOVEL CRYSTAL FORM THEREOF | REDWOOD, CHRISTOPHER EVAN | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18554679 | SULFATE OF 5-[(1,1-DIOXIDO-4-THIOMORPHOLINYL)METHYL]-2-PHENYL-N-(TETRAHYDRO-2H-PYRAN-4-YL)-1H-INDOLE-7-AMINE, AND NOVEL CRYSTAL FORM THEREOF | REDWOOD, CHRISTOPHER EVAN | 1629 | §112 | Non-Final OA | — | Pending | Oct 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMitoimmune Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Christopher Evan Redwood has the most, with 1 of Mitoimmune Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
